Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zettl

Showing results (291-300 of 1,084) with videos related to

Pageof 109
Sort By:
Der Nervenarzt|October 20, 2009
[Vaccination and multiple sclerosis]M Löbermann, A Winkelmann, E C Reisinger, et al.
CNS Neuroscience & Therapeutics|June 3, 2018
Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal periodAlexander Winkelmann, Paulus Stefan Rommer, Michael Hecker, et al.
Clinical and Experimental Immunology|September 5, 2013
Monoclonal antibodies in treatment of multiple sclerosisP S Rommer, A Dudesek, O Stüve, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 15, 1992
5'-Azido-[3,6-3H2]-1-napthylphthalamic acid, a photoactivatable probe for naphthylphthalamic acid receptor proteins from higher plants: identification of a 23-kDa protein from maize coleoptile plasma membranesR Zettl, J Feldwisch, W Boland, et al.
Cell|March 29, 2011
Rhomboid family pseudoproteases use the ER quality control machinery to regulate intercellular signalingMarkus Zettl, Colin Adrain, Kvido Strisovsky, et al.
Science (New York, N.Y.)|January 17, 2012
Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACEColin Adrain, Markus Zettl, Yonka Christova, et al.
Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS|October 30, 1999
[Transport trauma: fact or fiction?]R Zettl, C Waydhas, S Ruchholtz, et al.
Urologia Internationalis|January 26, 2025
The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A Single-Center ExperienceMoustafa Elleisy, Heike Zettl, Desiree Louise Dräger, et al.
Current Pharmaceutical Design|November 1, 2006
Comparative genomics for the investigation of autoimmune diseasesSteffen Möller, Uwe K Zettl, Pablo Serrano-Fernández, et al.
Clinical and Experimental Immunology|October 19, 2013
Multiple sclerosis treatment and infectious issues: update 2013A Winkelmann, M Loebermann, E C Reisinger, et al.
Pageof 109

Showing results (291-300 of 1,084) with videos related to

Sort By:
Pageof 109
Der Nervenarzt|October 20, 2009
[Vaccination and multiple sclerosis]M Löbermann, A Winkelmann, E C Reisinger, et al.
CNS Neuroscience & Therapeutics|June 3, 2018
Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal periodAlexander Winkelmann, Paulus Stefan Rommer, Michael Hecker, et al.
Clinical and Experimental Immunology|September 5, 2013
Monoclonal antibodies in treatment of multiple sclerosisP S Rommer, A Dudesek, O Stüve, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 15, 1992
5'-Azido-[3,6-3H2]-1-napthylphthalamic acid, a photoactivatable probe for naphthylphthalamic acid receptor proteins from higher plants: identification of a 23-kDa protein from maize coleoptile plasma membranesR Zettl, J Feldwisch, W Boland, et al.
Cell|March 29, 2011
Rhomboid family pseudoproteases use the ER quality control machinery to regulate intercellular signalingMarkus Zettl, Colin Adrain, Kvido Strisovsky, et al.
Science (New York, N.Y.)|January 17, 2012
Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACEColin Adrain, Markus Zettl, Yonka Christova, et al.
Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS|October 30, 1999
[Transport trauma: fact or fiction?]R Zettl, C Waydhas, S Ruchholtz, et al.
Urologia Internationalis|January 26, 2025
The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A Single-Center ExperienceMoustafa Elleisy, Heike Zettl, Desiree Louise Dräger, et al.
Current Pharmaceutical Design|November 1, 2006
Comparative genomics for the investigation of autoimmune diseasesSteffen Möller, Uwe K Zettl, Pablo Serrano-Fernández, et al.
Clinical and Experimental Immunology|October 19, 2013
Multiple sclerosis treatment and infectious issues: update 2013A Winkelmann, M Loebermann, E C Reisinger, et al.
Pageof 109